Engelking L R, Lofstedt J, Blyden G T, Greenblatt D J
Pharmacology. 1987;34(4):192-200. doi: 10.1159/000138269.
The following studies were designed to evaluate plasma elimination kinetics of intravenously administered antipyrine, acetaminophen and lidocaine among 9 healthy adult horses and 9 healthy drug-free humans (3 each per drug group), in order to compare potential species differences in drug-metabolizing ability. Acetaminophen is largely biotransformed in humans by hepatic glucuronide and sulfate conjugation, whereas both antipyrine and lidocaine are oxidized by hepatic microsomal mixed-function oxidases. Thus, plasma clearances of these drugs are thought to reflect differences in hepatic oxidative and conjugative activity, and possibly hepatic blood flow in the case of lidocaine. Results showed that mean (+/- SD, n = 3) acetaminophen clearance was similar in both horses (4.84 +/- 0.637 ml/min/kg) and humans (4.68 +/- 0.691 ml/min/kg). However, antipyrine clearance was 10 times greater in horses (5.83 +/- 2.21 ml/min/kg) than in humans (0.536 +/- 0.110 ml/min/kg), which may reflect enhanced hepatic microsomal activity in horses. Although lidocaine clearance in humans was similar to estimated hepatic blood flow (20.6 +/- 5.81 ml/min/kg), clearance in horses was more than 2 times greater (52.0 +/- 11.7 ml/min/kg). The cause of the higher clearance of lidocaine in horses (like dogs) remains unexplained, and may involve significant metabolism of lidocaine at extrahepatic, extravascular sites, for intravascular degradation and renal excretion of intact lidocaine in horses was negligible. Although precise biochemical mechanisms underlying pharmacokinetic parameters for these drugs in horses were not determined, it is nonetheless concluded from antipyrine results that horses may have an enhanced ability (compared with humans) to clear drugs from the circulation that are primarily metabolized in the liver by phase I oxidative reactions.(ABSTRACT TRUNCATED AT 250 WORDS)
以下研究旨在评估9匹健康成年马和9名健康且未服用药物的人类(每种药物组各3人)静脉注射安替比林、对乙酰氨基酚和利多卡因后的血浆消除动力学,以比较药物代谢能力方面潜在的物种差异。对乙酰氨基酚在人体内主要通过肝脏葡萄糖醛酸和硫酸盐结合进行生物转化,而安替比林和利多卡因均由肝脏微粒体混合功能氧化酶氧化。因此,这些药物的血浆清除率被认为反映了肝脏氧化和结合活性的差异,对于利多卡因而言,可能还反映了肝脏血流量的差异。结果显示,马(4.84±0.637毫升/分钟/千克)和人类(4.68±0.691毫升/分钟/千克)的平均(±标准差,n = 3)对乙酰氨基酚清除率相似。然而,马(5.83±2.21毫升/分钟/千克)的安替比林清除率比人类(0.536±0.110毫升/分钟/千克)高10倍,这可能反映出马肝脏微粒体活性增强。虽然人类利多卡因清除率与估计的肝脏血流量(20.6±5.81毫升/分钟/千克)相似,但马的清除率则高出2倍多(52.0±11.7毫升/分钟/千克)。马(与狗一样)利多卡因清除率较高的原因尚不清楚,可能涉及肝外、血管外部位对利多卡因的显著代谢,因为马体内完整利多卡因的血管内降解和肾排泄可忽略不计。虽然未确定这些药物在马体内药代动力学参数背后的确切生化机制,但从安替比林的结果可得出结论,马(与人类相比)可能具有更强的从循环中清除主要在肝脏通过I相氧化反应代谢的药物的能力。(摘要截选至250词)